ICAM1 and neoplasm: Once palpable tumors started to form after orthotopic implantation of MDA-MB-231 cells, anti-ICAM1 or IgG was administered twice a week for 4 weeks with both intravenous dosage (80 μg/mouse) via tail vein and subcutaneous dosages into the 4th mammary fat pads near tumor implants (10 μg/tumor, both left and right sides).